IL17A and inflammatory skin disease: In particular, the cytokines IL-17A and IL-13 that are current targets of clinical therapy for the skin inflammatory diseases psoriasis and AD have receptors expressed on keratinocytes, and it has been postulated that the efficacy of neutralizing these cytokines in suppressing disease symptoms is in part related to dampening keratinocyte activity.